Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity

Cancer Cell

Volumn 25, Issue 1, 2014, Pages 118-131

  Li, Jie ^a   Xu, Ying ^b   Long, Xi Dai ^c,d   Wang, Wei ^a   Jiao, Hui Ke ^b   Mei, Zhu ^a   Yin, Qian Qian ^b   Ma, Li Na ^a   Zhou, Ai Wu ^a   Wang, Li Shun ^a   Yao, Ming ^c   Xia, Qiang ^c   Chen, Guo Qiang ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d YOUJIANG MEDICAL COLLEGE FOR NATIONALITIES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIGASE; POLYCOMB GROUP PROTEIN; POLYCOMB GROUP PROTEIN CBX4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; SUMOYLATION; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; POLYCOMB-GROUP PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUMO-1 PROTEIN; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892387361     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.12.008     Document Type: Article

References (53)

1. Bae S.H., Jeong J.W., Park J.A., Kim S.H., Bae M.K., Choi S.J., Kim K.W. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 2004, 324:394-400.
2. Berta M.A., Mazure N., Hattab M., Pouysségur J., Brahimi-Horn M.C. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity. Biochem. Biophys. Res. Commun. 2007, 360:646-652.
3. Carbia-Nagashima A., Gerez J., Perez-Castro C., Paez-Pereda M., Silberstein S., Stalla G.K., Holsboer F., Arzt E. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 2007, 131:309-323.
4. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009, 6:465-477.
5. Cheng J., Kang X., Zhang S., Yeh E.T. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007, 131:584-595.
6. Dimova E.Y., Kietzmann T. Hypoxia-inducible factors: post-translational crosstalk of signaling pathways. Methods Mol. Biol. 2010, 647:215-236.
7. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
8. Feng G.S. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2012, 21:150-154.
9. Finn R.S., Zhu A.X. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev. Anticancer Ther. 2009, 9:503-509.
10. Fischle W., Wang Y., Jacobs S.A., Kim Y., Allis C.D., Khorasanizadeh S. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 2003, 17:1870-1881.
11. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
12. Gadelhak N.A., Gadelhak S.A., El-Morsi D.A., Abdelaziz M.M., Abbas A.T., El-Emshaty H.M. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Hepatogastroenterology 2009, 56:1417-1424.
13. Gil J., Bernard D., Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol. 2005, 24:117-125.
14. Goel H.L., Chang C., Pursell B., Leav I., Lyle S., Xi H.S., Hsieh C.C., Adisetiyo H., Roy-Burman P., Coleman I.M., et al. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov. 2012, 2:906-921.
15. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
16. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
17. Iakova P., Timchenko L., Timchenko N.A. Intracellular signaling and hepatocellular carcinoma. Semin. Cancer Biol. 2011, 21:28-34.
18. Kagey M.H., Melhuish T.A., Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 2003, 113:127-137.
19. Kang Y., Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013, 23:573-581.
20. Kang X., Li J., Zou Y., Yi J., Zhang H., Cao M., Yeh E.T., Cheng J. PIASy stimulates HIF1α SUMOylation and negatively regulates HIF1α activity in response to hypoxia. Oncogene 2010, 29:5568-5578.
21. Kaseb A.O., Morris J.S., Hassan M.M., Siddiqui A.M., Lin E., Xiao L., Abdalla E.K., Vauthey J.N., Aloia T.A., Krishnan S., Abbruzzese J.L. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J.Clin. Oncol. 2011, 29:3892-3899.
22. Klauke K., Radulović V., Broekhuis M., Weersing E., Zwart E., Olthof S., Ritsema M., Bruggeman S., Wu X., Helin K., et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat. Cell Biol. 2013, 15:353-362.
23. Klein U.R., Nigg E.A. SUMO-dependent regulation of centrin-2. J.Cell Sci. 2009, 122:3312-3321.
24. Koh M.Y., Powis G. Passing the baton: the HIF switch. Trends Biochem. Sci. 2012, 37:364-372.
25. Li B., Zhou J., Liu P., Hu J., Jin H., Shimono Y., Takahashi M., Xu G. Polycomb protein Cbx4 promotes SUMO modification of de novo DNA methyltransferase Dnmt3a. Biochem. J. 2007, 405:369-378.
26. Long J., Zuo D., Park M. Pc2-mediated sumoylation of Smad-interactingprotein 1 attenuates transcriptional repression of E-cadherin. J.Biol. Chem. 2005, 280:35477-35489.
27. Luis N.M., Morey L., Mejetta S., Pascual G., Janich P., Kuebler B., Cozutto L., Roma G., Nascimento E., Frye M., et al. Regulation of human epidermal stem cell proliferation and senescence requires polycomb- dependent and -independent functions of Cbx4. Cell Stem Cell 2011, 9:233-246.
28. Martin-Perez D., Piris M.A., Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010, 116:5465-5475.
29. Merrill J.C., Melhuish T.A., Kagey M.H., Yang S.H., Sharrocks A.D., Wotton D. A role for non-covalent SUMO interaction motifs in Pc2/CBX4 E3 activity. PLoS ONE 2010, 5:e8794.
30. Morey L., Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem. Sci. 2010, 35:323-332.
31. Müller J., Verrijzer P. Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr. Opin. Genet. Dev. 2009, 19:150-158.
32. Núñez-O'Mara A., Berra E. Deciphering the emerging role of SUMO conjugation in the hypoxia-signaling cascade. Biol. Chem. 2013, 394:459-469.
33. Okuno Y., Nakamura-Ishizu A., Otsu K., Suda T., Kubota Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat. Med. 2012, 18:1208-1216.
34. Peng X.Q., Wang F., Geng X., Zhang W.M. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Rev. Proteomics 2009, 6:551-561.
35. Pirrotta V. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 1998, 93:333-336.
36. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9:677-684.
37. Rapisarda A., Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 2012, 9:378-390.
38. Roscic A., Möller A., Calzado M.A., Renner F., Wimmer V.C., Gresko E., Lüdi K.S., Schmitz M.L. Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol. Cell 2006, 24:77-89.
39. Rosmorduc O., Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin. Liver Dis. 2010, 30:258-270.
40. Sauvageau M., Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299-313.
41. Schwartz Y.B., Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat. Rev. Genet. 2007, 8:9-22.
42. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
43. Smits M., Mir S.E., Nilsson R.J., van der Stoop P.M., Niers J.M., Marquez V.E., Cloos J., Breakefield X.O., Krichevsky A.M., Noske D.P., et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 2011, 6:e16282.
44. Su H.L., Li S.S. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002, 296:65-73.
45. Tatham M.H., Kim S., Yu B., Jaffray E., Song J., Zheng J., Rodriguez M.S., Hay R.T., Chen Y. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation. Biochemistry 2003, 42:9959-9969.
46. Vandamme J., Volkel P., Rosnoblet C., Le Faou P., Angrand P.O. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. Mol Cell Proteomics 2011, 10. M110 002642.
47. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
48. Wotton D., Merrill J.C. Pc2 and SUMOylation. Biochem. Soc. Trans. 2007, 35:1401-1404.
49. Yang H., Xiong Y., Guan K. Metabolic alteration in tumorigenesis. Sci. China Life Sci. 2013, 56:1067-1075.
50. Yuan W.C., Lee Y.R., Huang S.F., Lin Y.M., Chen T.Y., Chung H.C., Tsai C.H., Chen H.Y., Chiang C.T., Lai C.K., et al. A Cullin3-KLHL20Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 2011, 20:214-228.
51. Zhang L., Wang J.N., Tang J.M., Kong X., Yang J.Y., Zheng F., Guo L.Y., Huang Y.Z., Zhang L., Tian L., et al. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol. Biol. Rep. 2012, 39:5085-5093.
52. Zhao X., Yang Z., Li G., Li D., Zhao Y., Wu Y., Robson S.C., He L., Xu Y., Miao R., Zhao H. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci. China Life Sci. 2012, 55:906-919.
53. Zhu A.X., Duda D.G., Sahani D.V., Jain R.K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 2011, 8:292-301.